ADVFN - Advanced Financial Network.
HOME» NASDAQ » V » VICL Stock Price » VICL Stock News

Vical Share News

 Vical Incorporated (mm) Stock Price
VICL Stock Price
 Vical Incorporated (mm) Stock Chart
VICL Stock Chart
 Vical Incorporated (mm) Stock News
VICL Stock News
 Vical Incorporated (mm) Company Information
VICL Company Information
 Vical Incorporated (mm) Stock Trades
VICL Stock Trades

Biopharmaceutical Co Vical Prices 13.3M Share Offering At 12% Discount

DOW JONES NEWSWIRES Biopharmaceutical developer Vical Inc.'s (VICL) public offering of 13.3 million shares priced at a 12% discount from Thursday's close. Shares were recently trading at $3.79, slightly above the offering price of $3.75. Vical develops gene-based treatments for cancer as well as vaccines for infectious diseases. Last year, it signed a $130 million licensing deal with Japan's Astellas Pharma Inc. (4503.TO, ALPMY) to develop and sell its TransVax cytomegalovirus vaccine. Like many development-stage drug makers, it posts frequent losses. The company, which had about 73.7 million outstanding shares as of Nov. 1, outlined plans to offer stock late Thursday but didn't detail how many shares it intended to offer. The firm expects to use the proceeds for general corporate purposes, including clinical trial expenses, research and development and other working capital. In November, Vical said it swung to a third-quarter profit on a large increase in license and royalty revenue. -By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com;

Stock News for Vical (VICL)
DateTimeHeadline
02/04/201606:05:25Current Report Filing (8-k)
01/27/201615:44:14Amended Statement of Ownership (sc 13g/a)
01/26/201615:07:53Statement of Changes in Beneficial Ownership (4)
01/15/201618:44:35Statement of Changes in Beneficial Ownership (4)
01/15/201618:41:20Statement of Changes in Beneficial Ownership (4)
01/15/201618:36:41Statement of Changes in Beneficial Ownership (4)
01/13/201614:37:09Statement of Changes in Beneficial Ownership (4)
01/13/201614:32:34Statement of Changes in Beneficial Ownership (4)
01/08/201618:08:35Statement of Changes in Beneficial Ownership (4)
01/06/201606:30:00FDA Grants Vical Orphan Drug Designation for VL-2397 for the...
12/22/201517:34:14Statement of Changes in Beneficial Ownership (4)
12/22/201515:25:09Initial Statement of Beneficial Ownership (3)
12/21/201516:16:19Current Report Filing (8-k)
12/21/201516:15:00Vical Appoints Dr. Thomas Shenk to Board of Directors
12/15/201514:39:42Confidential Treatment Order (ct Order)
11/11/201508:00:00Vical to Present at the Stifel Healthcare Conference 2015
10/30/201516:46:15Quarterly Report (10-q)
10/29/201506:31:59Current Report Filing (8-k)
10/29/201506:30:00Vical Reports Third Quarter 2015 Financial Results and Progress...
10/27/201512:38:48Statement of Changes in Beneficial Ownership (4)

Vical and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad